CD274 and renal cell carcinoma: The combination therapies of PD-1 or PDL-1 with other checkpoint inhibitors are in clinical trials, such as (i) a phase I study (NCT01968109) of “nivolumab + BMS-936558” for targeting PD1/LAG3 in advance solid tumor; (ii) a phase II study (NCT02845323) of “nivolumab + urelumab” for targeting PD1/4-1BB in B-cell lymphoma; and (iii) a phase II study (NCT02543645) of “atezolizumab + varlilumab” for targeting PDL1/CD27 in RCC (Morrissey et al., 2016).